Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) Revenue (2019 - 2023)

Benitec Biopharma (BNTC) has disclosed Revenue for 5 consecutive years, with $7000.0 as the latest value for Q2 2023.

  • Quarterly Revenue changed N/A to $7000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $7000.0 through Mar 2024, down 89.71% year-over-year, with the annual reading at $75000.0 for FY2023, 2.74% up from the prior year.
  • Revenue hit $7000.0 in Q2 2023 for Benitec Biopharma, down from $54000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $77000.0 in Q4 2019 to a low of -$35000.0 in Q2 2020.
  • Historically, Revenue has averaged $23846.2 across 5 years, with a median of $25000.0 in 2021.
  • Biggest five-year swings in Revenue: crashed 98.7% in 2020 and later surged 4700.0% in 2022.
  • Year by year, Revenue stood at $77000.0 in 2019, then plummeted by 98.7% to $1000.0 in 2020, then skyrocketed by 2400.0% to $25000.0 in 2021, then crashed by 44.0% to $14000.0 in 2022, then plummeted by 50.0% to $7000.0 in 2023.
  • Business Quant data shows Revenue for BNTC at $7000.0 in Q2 2023, $54000.0 in Q1 2023, and $14000.0 in Q4 2022.